Severe Alcohol-Associated Hepatitis research hub

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects with Severe Alcohol-Associated Hepatitis

This study looks into a new medication called INT-787 for people with severe liver damage caused by alcohol. Doctors want to see if it's safe, if patients tolerate it well, and if it helps improve their condition more than a dummy treatment.